Evidence map›Paper›PMID 41978543›Full record

ArticleNeuro-oncology2026

CNS tumor type prevalence according to age group: An analysis of 21 000 cases confirmed by methylation profiling, with a focus on adolescents and young adults.

Adriana Fonseca, Leeor Yefet, Omkar Singh, Christopher Dampier, Karen Dazelle, Michelle Lam, Zied Abdullaev, Hye-Jung Chung, Martha Quezado, Mark Raffeld and 14 more

Abstract read
In one paragraph

Article in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Adriana FonsecaBrain Tumor Institute, Children's National Hospital, Washington, District of Columbia, USA.ORCID 0000-0002-6382-6833
Leeor YefetDepartment of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
Omkar SinghLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-4500-7519
Christopher DampierLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-3099-6462
Karen DazelleLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0009-0006-1357-2384
Michelle LamLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0009-0009-2167-506X
Zied AbdullaevLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-6345-2088
Hye-Jung ChungLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Martha QuezadoLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0009-0004-0941-8662
Mark RaffeldLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-4039-6957
Jeffrey GaganLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-4676-9969
Ina LeeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-6082-6395
MacLean NasrallahDivision of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-4861-0898
Julie BennettDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.ORCID 0000-0002-4146-1511
Eric BouffetDivision of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.ORCID 0000-0002-6832-6539
Dipak PoriaBrain Tumor Institute, Children's National Hospital, Washington, District of Columbia, USA.ORCID 0000-0002-6935-4160
Pieter WesselingDepartment of Pathology, Amsterdam University Medical Centers/VU University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0001-5453-5201
Martin van den BentDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0001-5710-5127
Patrick Y WenCenter for Tumors of the Nervous System, Mass General Brigham Cancer Institute, Boston, Massachusetts, USA (P.Y.W.).ORCID 0000-0002-0774-7700
Pascale VarletDepartment of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.ORCID 0000-0002-8164-1517
Arnault Tauziède-EspariatDepartment of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.ORCID 0000-0002-9979-0297
Cristiane M IdaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-2768-2913
Gelareh ZadehDepartment of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0009-0009-2002-5313
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-5119-7550

Funding

Single-cell DNA methylation analysis of human cancerZIABC011846 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALDAPE, KENNETH · 2018 to 2025
$8.4M
Children's National Hospital, Brain Tumor InstituteIntramural NIH HHS ZIA BC011846NIH HHS 1ZIABC011846
6 · The paper itself

Abstract

backgroundApproximately 12 000 adolescents and young adults (ages 15-39, AYAs) are diagnosed with a primary central nervous system (CNS) tumor each year. DNA methylation profiling has transformed CNS tumor classification by refining diagnostic accuracy and identifying biologically distinct subtypes, but its application has not been systematically evaluated in the AYA population. In this study, we examined the spectrum of CNS tumor types across age groups, with a focus on the AYA population.

methodsWe assembled a large dataset of CNS tumor samples with age annotations and methylation profiles matching with high confidence to a CNS tumor type using the NCI/Bethesda classifier. Prevalence of tumor type, methylation class and DNA copy number aberrations were compared across age strata (pediatric, AYA, and adult).

resultsThe cohort of 21 712 CNS tumors included 5351 tumors from AYAs (25%), which showed a mixed pattern, with tumors typical of childhood (eg, medulloblastoma) as well as those common in older adults (eg, glioblastoma). Several tumor types were specifically enriched in the AYA, including IDH-mutant astrocytoma, pleomorphic xanthoastrocytoma, posterior fossa group B ependymoma, and diffuse hemispheric glioma, H3 G34-mutant, among others. Distinct methylation subclasses of multiple tumor types were observed in the AYA, and patterns of genomic aberrations showed age-specific distributions.

conclusionLarge-scale methylation profiling revealed unique classification patterns of CNS tumors in AYAs, with specific tumor types, subclasses, and genomic alterations enriched in this population. These data may serve as a valuable reference resource for better understanding the spectrum of CNS tumors affecting AYA patients.

Indexed as

Biomarkers, TumorCentral Nervous System NeoplasmsDNA MethylationAdolescentAdultAge FactorsChildFemaleHumansMalePrevalencePrognosisYoung AdultBiomarkers, Tumoradolescents and young adultsAYADNA methylation classificationtumor types

Identifiers

PMID41978543
PMCPMC13255572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.